Biogen IDEC Inc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 284 Posts
1 2 3 ... 18
Investors Too Gloomy Over Biogen Alzheimer’s Drug
Article By: Lipper Alpha Insight Friday, July 23, 2021 8:02 AM EDT
There are good reasons to be skeptical that Biogen’s Aduhelm, the first new treatment for Alzheimer’s disease in nearly two decades, will change patients’ lives for the better.
In this article: BIIB
Read
Biogen's Q2 Profit Falls 70% As Tecfidera Competition Hits Topline
Article By: Benzinga Thursday, July 22, 2021 9:56 AM EDT
Biogen Inc posted Q2 adjusted EPS of $5.68 ahead of the consensus estimate of $4.55, but quarterly profit fell around 71% Y/Y to $448.5 million as competition intensified for the Company's flagship product, Tecfidera, a multiple sclerosis drug.
In this article: BIIB
Read
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Article By: Benzinga Sunday, July 18, 2021 11:25 AM EDT
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks.
In this article: ABT, DGX, JNJ, LLY, NURO, BIIB, ISRG, FGEN, ALBO, MRNA
Read
Biogen Slides As FDA Calls For Investigation Into Approval Of Controversial Alzheimer's Drug
Article By: Tyler Durden Friday, July 9, 2021 2:48 PM EDT
Shares of Biogen sank to their lowest levels of the session, weighing on the broader biotech sector.
In this article: BIIB
Read
Weekly Trade With Yield Up To 575%
Article By: Financial Velociraptor Tuesday, July 6, 2021 11:28 PM EDT
With CTAS trading at 378.13, I bought the 370/380 bull call spread with 20AUG2021 expiry for 5.80 a share (8 spreads).
In this article: BIIB, CTAS
Read
Friday Trades And June Summary
Article By: Financial Velociraptor Saturday, July 3, 2021 9:14 PM EDT
Trading performance has been very good year to date. I had thought I needed to tighten my belt but I made it by just fine.
In this article: BIB, BIIB, ROM Also: XLM-X, ALGO-X
Read
2 Large Cap Biotech Stocks Up More Than 25% In The Last Month
Article By: StockNews Tuesday, June 15, 2021 10:32 AM EDT
Biotech stocks are an area of the market that can deliver massive returns to investors, however, this potential reward does come with massive risk.
In this article: BNTX, BIIB Also: PFE
Read
EC Biotechs Ready To Roar
Article By: Tarun Chandra, CFA Sunday, June 13, 2021 11:15 AM EDT
The recent FDA decision will reverberate across the industry and the healthcare sector for many reasons.
In this article: BIIB Also: LLY, IBB, XBI, XLV, SUPN, ITCI, BHVN, DNLI, SAVA, KRTX, ARVN, ANVS, INMB, AVXL, PRTA
Read
U.S. Approves Biogen's Alzheimer's Drug
Article By: Admiral Markets Tuesday, June 8, 2021 9:00 AM EDT
During yesterday's session, the US pharmaceutical company based in Massachusetts, Biogen, experienced a strong rebound in the stock market after the FDA approved the use of its Alzheimer's drug known as Aduhelm.
In this article: BIIB
Read
Biogen Gets FDA Nod For Controversial Alzheimer's Drug; First Treatment Approval For The Disease In 18 Years
Article By: Benzinga Monday, June 7, 2021 12:26 PM EDT
Biogen's biologics license application for aducanumab, its investigational Alzheimer's treatment, received FDA approval under the accelerated approval pathway.
In this article: BIIB
Read
5 Stocks To Sell In May
Article By: Money Morning Thursday, May 6, 2021 5:06 AM EDT
Just about every investor has heard the old standby "sell in May and go away" around this time of year.
In this article: MCHP, JD, BIDU, BIIB, CTXS Also: SOX
Read
Alzheimer's Disease: 5 Stocks On Biotech Radars
Video By: Kevin Cook Thursday, April 22, 2021 7:53 PM EDT
What's been interesting for the past couple of years, and especially the last few months, is to watch the rise of emerging, small-cap Biotech companies trying to take on the big AD and other neurological and CNS diseases.
In this video: AVXL, JAZZ, BIIB, AXSM, SAVA
Watch
Biogen's Shares Are Trading Lower On 71% Quarterly Profit Slump, Weak Tecfidera Sales
Article By: Benzinga Thursday, April 22, 2021 12:01 PM EDT
Biogen Inc reported a 70.7% fall in Q1 profit as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic drugs.
In this article: BIIB
Read
E Portfolio Hi-Lites: March 2021
Article By: Ingrid Hendershot Thursday, March 11, 2021 12:30 PM EDT
During the past three months, the S&P 500 index rose 7.1% as vaccines started rolling out and investors looked forward to a more “normal” 2021. The following HI quality stocks generated 10% or better gains during the same period.
In this article: CSCO, GD, GPC, MMS, BIIB, FFIV, INTC, ORCL, TROW, TSCO, ULTA, WBA, RTX
Read
How Will Biotech ETFs React To These Q4 Earnings Releases?
Article By: Zacks Investment Research Saturday, February 6, 2021 4:47 PM EDT
Any positive news highlighting the progress of vaccine or antibody manufacturers is expected to create great returns for investors. Let’s take a look at some biotechnological earnings releases to see if these will impact ETFs exposed to the space.
In this article: BBH, IBB, XBI, BIIB, ALXN, GILD, AMGN
Read
Biogen Inc. (BIIB) Misses Q4 Earnings Estimates
Article By: Zacks Investment Research Wednesday, February 3, 2021 10:38 AM EDT
Biogen Inc. came out with quarterly earnings of $4.58 per share, missing the Zacks Consensus Estimate of $4.93 per share.
In this article: BIIB
Read
1 to 16 of 284 Posts
1 2 3 ... 18